Does Wegovy break down fat, or does it work another way?

What the STEP 1 trial showed about fat loss on semaglutide

The clearest window into how Wegovy works comes from the STEP 1 trial, published in the New England Journal of Medicine. Over 68 weeks, adults living with obesity who took semaglutide 2.4mg weekly alongside lifestyle changes lost an average of around 15% of their starting body weight, versus under 3% in the placebo group. Body-composition analyses confirmed that the vast majority of that loss was fat mass, not lean tissue, though preserving muscle requires adequate protein intake and activity.

The trial did not show semaglutide dissolving fat cells. What it showed was a sustained calorie deficit, maintained because participants ate less, not by willpower alone, but because the medicine changed how hungry they felt and how quickly they felt full. Fat stores shrank as a consequence of that deficit over many months. That is a meaningfully different mechanism from, say, a lipase inhibitor like orlistat, which blocks fat absorption in the gut.

Understanding this also explains the timescale. Wegovy does not produce rapid visible changes in the first days of treatment. The 15% average figure came after 68 weeks of consistent use alongside diet and activity support, the NHS semaglutide medicines page notes that full effects build gradually.

The actual mechanism: GLP-1 receptors, appetite, and the gut-brain signal

A question our prescribers hear most weeks is whether Wegovy is a fat burner, and the honest answer is no, not in the sense most people mean. Semaglutide is a GLP-1 receptor agonist. It mimics a hormone your gut releases after eating, binding to receptors in the brain's appetite centres and in the gut wall itself. The result is a reduction in hunger signals and an increase in feelings of satiety.

There is also a mechanical element. Wegovy slows gastric emptying (the rate at which food leaves the stomach) which prolongs fullness after a meal. You can read more about this specific effect on our page about how Wegovy affects digestion. The combined effect is that people tend to eat smaller portions and feel satisfied sooner, often without making a conscious effort to restrict.

Once a consistent calorie deficit is established over weeks, the body begins drawing on fat stores for energy. That is where the fat loss originates, not from a direct lipolytic action of the medicine, but from the body's own metabolic response to reduced energy intake. The medicine creates the conditions; biology does the rest.

What this means for body composition during treatment

Because semaglutide produces its effects through appetite reduction rather than a direct action on fat tissue, the quality of the diet during treatment influences what kind of weight is lost. Periods of very low intake can result in some lean-mass loss alongside fat loss, which is why clinical guidance emphasises adequate protein, regular meals and physical activity (particularly resistance exercise) during treatment.

This is also why the Wegovy overview on our site emphasises that the medicine works alongside lifestyle changes, not instead of them. The licensed indication specifically requires a reduced-calorie diet and increased physical activity. A prescriber will discuss this during your assessment, and it is worth thinking about in advance. If you are weighing up options, our weight-loss treatments page outlines how different approaches compare.

One practical note: the effect on appetite can be strong enough that some people eat too little, especially in the early weeks. That is not safer, it can accelerate lean-tissue loss and cause nutritional gaps. If eating enough feels difficult, it is worth raising with your prescriber rather than assuming less is better.

Stopping treatment and what happens to fat stores

Because Wegovy acts on appetite via an ongoing hormonal signal rather than permanently changing fat tissue, the effects are not permanent without continued treatment. When people stop semaglutide, the GLP-1 receptor agonism ends, appetite signals return towards their baseline, and weight regain is common, a pattern documented across the STEP trial programme. Our pages on taking a break from Wegovy and whether breaks are advisable cover this in detail, and if you are wondering whether taking a break from semaglutide is an option for you, that page walks through what the evidence says.

This is not a failing of the medicine. It reflects that obesity has a persistent biological component, the body defends its higher weight set-point through multiple hormonal mechanisms. The cost context of long-term treatment is worth understanding too; our Wegovy pricing page explains what private treatment typically involves. Any decision about duration, pausing or stopping should be made with a prescriber, not acted on unilaterally.

If you would like to understand whether Wegovy may be suitable for you, speak to our prescribers through a free consultation, reviewed the same day by a GPhC-registered prescriber, not automated software.